Stefania Federica De Mercanti

COVID-19 Severity in Multiple Sclerosis

Maria Pia Sormani, Irene Schiavetti, Luca Carmisciano et al. · Neurology Neuroimmunology & Neuroinflammation · 2021 · 74 citations · Full text

Public Health, Internal Medicine, Clinical Epidemiology +16

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab

Marinella Clerico, Irene Schiavetti, Stefania Federica De Mercanti et al. · JAMA Neurology · 2014 · 52 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +14

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Marinella Clerico, Stefania Federica De Mercanti, Alessio Signori et al. · Neurotherapeutics · 2019 · 52 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Maria Pia Sormani, Irene Schiavetti, Doriana Landi et al. · Multiple Sclerosis Journal · 2021 · 52 citations · Full text

Life Sciences, Clinical Sciences, Immunology +14

A real‐world study of alemtuzumab in a cohort of Italian patients

Cinzia Valeria Russo, Francesco Saccà, Jessica Frau et al. · European Journal of Neurology · 2021 · 26 citations · Full text

Medicine, Neurology, Pharmacotherapy +16